Abstract Purpose: To elicit a long-lasting antitumor immune response, CD8
CD4
+ helper T cells play an important role in orchestrating the effector function of antitumor T-cell responses (1) , and for this reason, the identification of CD4 + T-cell epitopes derived from tumor-associated antigens (TAA) has recently been a major focus of attention (2, 3) . Even in the absence of CTL effector cells, helper T cells in the mouse can inhibit tumor angiogenesis via IFNg (4) and counteract tumor progression via the induction of an antibody response (5) . In contrast to HLA class I ligands, only a small number of class II ligands of TAA has been described. Because HLA class II molecules are constitutively presented on cells of the immune system alone (6) , the possibility of isolating class II peptides directly from primary tumors as opposed to class I ligands (7) has not been considered viable. Therefore, numerous strategies to target antigens into the class II processing pathway of antigenpresenting cells have been described (e.g., the incubation of antigen-presenting cells with the antigen of interest to enable it to be taken up, processed, and presented; ref. 8) .
To identify HLA class II ligands from TAA for their use in peptide-based immunotherapy, we attempted to isolate HLA-DR -presented peptides directly from dissected solid tumors, in particular from renal cell carcinoma (RCC). Even if the majority of tumor cells were class II negative, with state-of-the-art mass spectrometers, it should be possible to identify class II peptides from minimal numbers of tumor cells, from infiltrating immune cells possibly cross-presenting TAA, and from stromal cells.
The reasons for concentrating on RCC are the following: Around 150,000 people worldwide are affected by RCC each year, resulting in f78,000 deaths per annum (9) . If metastasis is diagnosed, the 1-year survival rate decreases to f60% (10) , underlining the dissatisfactory therapeutic situation. Because RCC seems to be an immunogenic tumor, as indicated by the existence of tumor-reacting and tumor-infiltrating CTL (11) , clinical trials have been initiated to develop peptide-based antitumor vaccinations. However, due to the lack of helper T-cell epitopes from TAA, molecularly defined vaccines usually comprise class I ligands only.
We were able to isolate class II ligands from nine RCCs, three colorectal carcinomas, and two transitional cell carcinomas (urothelial carcinoma). Selected ligands of TAA promiscuously binding to HLA-DR molecules were found to be recognized by CD4 + T cells.
Materials and Methods
Patient samples. The majority of patient samples were obtained from the Department of Urology, University of T ü bingen. The local ethical committee approved the study, and informed consent was obtained from the patients. Patient information is provided in Supplementary  Table S1 .
MHC class II immunohistology. Tumors were fixed in 4% phosphatebuffered formaldehyde, embedded in paraffin, stained with H&E, and examined by light microscopy. Diagnosis of the RCC was carried out according to routine histopathologic and immunohistologic investigations (12) .
For immunohistologic detection of MHC class II molecules or CD68 molecules, respectively, 5-Am paraffin-embedded tissue sections were pretreated with 10 mmol/L citrate buffer (pH 6) followed by incubation either with a mouse anti-HLA-DR a-chain monoclonal antibody (clone TAL.1B5, 1:50) or CD68 antibody (Clone PGM1, 1:50; DAKO, Hamburg, Germany) or mouse IgG1 (2 Ag/mL, BD Biosciences PharMingen, San Diego, CA) and visualized using the Ventana iView 3,3 ¶-diaminobenzidine detection kit (Nexes System, Ventana Medical Systems, Illkirch, France). For the detection of CD4 + T lymphocytes, the tissue sections were pretreated with 1 mmol/L EDTA (pH 8) for 5 minutes in a pressure cooker before incubation with a monoclonal mouse anti-CD4 antibody (Ventana, clone 1F4) and further processing with the Nexes System as described above. Tissue sections were counterstained with hematoxylin and finally embedded in Entellan.
Elution and molecular analysis of HLA-DR -bound peptides. Frozen tumor samples were processed as previously described (7), and peptides were isolated according to standard protocols (13) using the HLA-DRspecific monoclonal antibody L243 (14) . Natural peptide mixtures were analyzed by a reversed-phase Ultimate HPLC system (Dionex, Amsterdam, the Netherlands) coupled to a Q-TOF I mass spectrometer (Waters, Eschborn, Germany), or by a reversed-phase CapLC HPLC system coupled to a Q-TOF Ultima API (Waters) as previously described (15) . Fragment spectra were analyzed manually and automatically.
Gene expression analysis by high-density oligonucleotide microarrays. RNA isolation from tumor and autologous normal kidney specimens as well as gene expression analysis by Affymetrix Human Fig. 1 . Expression of HLA class II molecules in RCC of two patients. The HLA class II expression patterns of the tumors from patient RCC190 and RCC211, revealing a papillary structure, were evenly spread (A, C, E, and G). Fig. S1E and F) . T, tumor.
Genome U133 Plus 2.0 oligonucleotide microarrays (Affymetrix, Santa Clara, CA) were done as described previously (16) . Data were analyzed with the GCOS software (Affymetrix). Pairwise comparisons between tumor and autologous normal kidney were calculated using the respective normal array as baseline. For RCC149 and RCC211, no autologous normal kidney array data were available. Therefore, pooled healthy human kidney RNA was obtained commercially (Clontech, Heidelberg, Germany) and used as the baseline for these tumors.
Maturation of dendritic cells. Dendritic cells were prepared using blood from healthy donors. Briefly, peripheral blood mononuclear cells (PBMC) were isolated using standard gradient centrifugation (Lymphocyte Separation Medium, PAA Laboratories GmbH, Pasching, Austria) and plated at a density of 7 Â 10 6 /mL in X-Vivo 15 medium. After 2 hours at 37jC, nonadherent cells were removed, and adherent monocytes were cultured for 6 days in X-Vivo medium with 100 ng/mL granulocyte macrophage colony-stimulating factor and 40 ng/mL interleukin-4 (ALImmunoTools, Friesoythe, Germany). On day 7, immature dendritic cells were activated with 10 ng/mL tumor necrosis factor-a (R&D Systems, Wiesbaden, Germany) and 20 Ag/mL poly(IC) (Sigma-Aldrich, Steinheim, Germany) for 3 days.
Generation of antigen-specific CD4 + T cells. PBMCs (10 6 per well) were stimulated with 2 Â 10 5 peptide-pulsed (5 Ag/mL) autologous dendritic cells. Cells were incubated in 96-well plates (seven wells per donor and per peptide) with T-cell medium: supplemented RPMI 1640 in the presence of 10 ng/mL interleukin-12 (Promocell, Heidelberg, Germany). After 3 to 4 days of coincubation at 37jC, fresh medium with 80 units/mL interleukin 2 (Proleukin, Chiron Corp., Emeryville, CA) and 5 ng/mL interleukin-7 (Promocell) was added. Restimulations were done with autologous PBMCs plus peptide every 6 to 8 days.
Intracellular IFNg staining. After three and four rounds of stimulation, PBMCs were thawed, washed twice in X-Vivo 15 medium, resuspended at 10 7 cells/mL in T-cell medium, and cultured overnight. On the next day, PBMCs pulsed with 5 Ag/mL peptide were incubated with effector cells in a ratio of 1:1 for 6 hours. Golgi-Stop (Becton Dickinson, Heidelberg, Germany) was added for the final 4 hours of incubation.
Cells were analyzed using a Cytofix/Cytoperm Plus kit (Becton Dickinson) and CD4-FITC (Immunotools), IFNg-PE, and CD8-PerCP clone SK1 antibodies (Becton Dickinson). For negative controls, cells of seven wells were pooled and incubated either with irrelevant peptide or without peptide, respectively. Stimulation with phorbol 12-myristate 13-acetate/Ionomycin was used for positive control. Cells were analyzed on a three-color FACSCalibur (Becton Dickinson).
Results
HLA class II expression by RCC. Under normal, noninflammatory conditions, class II molecules should only be expressed by cells of the hematopoietic system and by the thymic epithelium (6) . The situation changes during inflammation. MHC II expression can be induced in most cell types and tissues by IFNg (17) . As RCC incidence is often accompanied by inflammatory events (18, 19) , it has been reported that class II molecules might be expressed in the vicinity of or by tumors (20) .
We analyzed HLA class II expression of nine RCC specimens comprising histologic clear cell and papillary renal carcinoma (Supplementary Table S1 ) by immunohistochemical staining and found that all investigated samples revealed class IIpositive tumor cells. In RCC revealing a papillary architecture, the expression of HLA class II molecules was evenly distributed throughout the tumor (Fig. 1A, C Fig. S1 ) and colorectal carcinomas ( Supplementary Fig. S2 ).
To further elucidate the mechanism of class II expression on RCC, we did comparative gene expression analysis using oligonucleotide microarrays. With this technique, we were able to asses the overall class II expression in the dissected tumors regardless of the expressing cell types. We analyzed differential expression in four tumors (RCC149, RCC180, RCC190, and RCC211) compared with normal reference kidney. In all four tumors, HLA class II genes were overexpressed (Table 1) . One possible reason for this might be an induced expression by IFNg, and for this reason, we looked for other genes known to be up-regulated by IFNs (21) . Interestingly, a considerable number of such genes were found to be overexpressed in one or more tumor samples. Table 1 shows IFN-inducible genes that were up-regulated reproducibly in all four samples, in accordance with our earlier findings (7). Among them are LMP2, LMP7, and MECL1: proteins that are exchanged against constitutive proteasomal subunits to form the immunoproteasome, a hallmark process in an IFN-rich environment. Additionally, IFNg was directly assessed by quantitative realtime reverse transcription-PCR (Taqman). The tumors displayed in Table 1 showed at least a 5-fold IFNg mRNA overexpression compared with their autologous normal RNA samples (data not shown). Thus, our results show that IFNg might play an important role in RCC and is most likely the reason for abundant class II expression.
HLA-DR ligands isolated from dissected carcinomas. Class II peptides from primary solid tumors have thus far not been (Fig. 1) and shows that class II -positive tumor cells and infiltrating leukocytes were present in analyzed specimens. A clear distinction between different peptide pools is not possible. However, our data suggest that the eluted peptides derive from these distinct cell types. To identify peptides from TAA, we compared ligand source proteins with overexpressed genes detected by microarray analysis of tumors (7, 16) . We identified a peptide from insulin-like growth factor binding protein 3 (IGFBP3 166-181 ), on RCC190. In addition, two variants of this peptide (IGFBP3 169-181 and IGFBP3 169-184 ) were found on TCC108. From the same tumor, a peptide from MMP7 (MMP7 247-262 ) could be isolated (Supplementary Table S2) . At the mRNA level, IGFBP3 was overexpressed in 8 and MMP7 in 6 of 10 analyzed RCCs (Fig. 2) , and both have been described to be tumor associated (25 -27) . To test these peptides for their capacity to stimulate specific T-cell reactivities, the shortest variant of the IGFBP3 peptides (IGFBP3 [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] ) and the MMP7 peptide were used (Table 2B) . Table S2 ) in both cases. According to the epitope predictions for DRB1*1101 and DRB1*1501, both peptides received a high binding score for HLA-DRB1*11 (data not shown). To generate antigen-specific CD4 + T cells and to test the peptides for promiscuous binding, PBMCs of four healthy donors with different HLA-DR alleles (Fig. 3) , one of them carrying DRB1*1101, were stimulated using peptide-pulsed autologous dendritic cells. In addition, the peptide CCND1 198-212 , a known T-cell epitope (28), was used as positive control (Table 2B) . As a read-out system for the generation of antigen-specific CD4 + T cells, IFNg levels were assessed by flow cytometry. T cells were analyzed after the third and fourth weekly stimulation by intracellular IFNg staining plus CD4-FITC and CD8-PerCP staining to determine the percentage of IFNg-producing cells in specific T-cell subpopulations. In all experiments, stimulations with irrelevant peptide and without peptide were done as negative controls. IFNg response was considered as positive if the percentage of IFNg producing CD4 + T cells was >2-fold higher compared with negative controls (29) .
In three of four donors, we were able to generate specific CD4 + T cells for both peptides (Figs. 3 and 4) . T-cell responses could not be observed in donor 4 after any stimulation. In donor 1, 0.06% to 0.13% IFNg-producing CD4 + T cells (Fig. 4 ) were detected in six of seven stimulation attempts after the fourth stimulation with peptide IGFBP3 169-181 . IFNg-producing CD4 + T cells specific for the peptide IGFBP3 169-181 were also observed in donors 2 and 3, with maximal frequencies of 0.11% and 0.07%. Donors 1, 2, and 3 also showed CD4 + T cells reactive to peptide MMP7 247-262 . The highest frequencies of IFNgproducing CD4 + T cells specific for the MMP7 peptide were found in donors 1 and 2, respectively. Donors 1, 2, and 3 showed IFNg responses to peptide CCND1 [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] , which has already been described as an MHC class II-restricted T-cell epitope (28) .
Thus, peptides from IGFBP3, MMP7, and CCND1 are promiscuous HLA class II binders that are able to elicit CD4 + T-cell responses in three of four healthy donors carrying different HLA alleles. Comparing the HLA alleles of the two tumor patients from which the IGFBP3 and MMP7 peptides were derived with those of the four healthy donors, it seems very likely that the peptides are presented by HLA-DRB1*01, HLA-DRB1*04, and HLA-DRB1*11. All three allotypes have a glycine residue at position 86 and an aspartic acid residue at position 57 of their h chains (see http://www.anthonynolan.com/HIG). Therefore, they have very similar binding characteristics for their binding pockets P1 and P9 (30) . For peptide CCND1 198-212 , a T-cell epitope known to be presented by HLA-DRB1*0401 and HLA-DRB1*0408 (28), the same holds true. Donor 4 carries HLA-DRB1*0318 and HLA-DRB1*1401, alleles with peptide motifs that probably differ from those described above. This could explain why it was not possible to elicit T-cell responses against the three peptides using cells from this donor.
Interestingly, IFNg-producing CD8 + T cells were detected in two donors after stimulations with the three peptides, in particular in donor 3, but also to a lesser extent in donor 1 (data not shown). These observations suggest the presence of CD8 T-cell responses directed against class I epitopes included in the long class II peptides (31) .
We also analyzed patient tumor-infiltrating T cells and PBMCs ex vivo or after one in vitro presensitization in the presence of the relevant peptides for reactivity against peptides IGFBP3 169-181 and MMP7 247-262 by intracellular IFNg staining. Only in one of 12 cases (RCC149) we were clearly able to detect Supplementary Fig. S3 ). However, this effect was not seen anymore after the 4th stimulation.
MMP7-specific CD4
+ T cells after 8 days of culture (Supplementary Fig. S4 ; Supplementary Table S3) . In this donor, the restriction element was most probably HLA-DRB1*01. We did not detect IGFBP3-specific T cells. These results suggest that spontaneous CD4 + T-cell responses against the two MMP7 and IGFBP3 peptides are rare in RCC patients and/or happen at very low frequencies, which were not detected after one or two in vitro stimulations with peptides.
Discussion
The identification of helper T-cell epitopes of TAA remains an important task in antitumor immunotherapy. To elicit a longlasting antitumor immune response, CD8 + and CD4 + T cells should be activated (32) . The isolation and identification of tumor-associated class I peptides from solid carcinomas has been successfully employed (7) . However, as class II molecules should be constitutively presented exclusively on cells of the immune system, this approach has not been used for the identification of class II peptides. Laborious strategies for the characterization of class II peptides from TAA have been carried out until now, ranging from the incubation of antigenpresenting cells with the antigen of interest to be taken up and processed (8) to various transfection strategies with fusion proteins (28) . All these methods are very time consuming, and it often remains unclear if the identified ligands are presented in vivo. We could show for the first time that it is possible to isolate class II ligands directly from dissected solid tumors, thus identifying the peptides that are presented by tumors and surrounding tissue in vivo. Among the source proteins, several housekeeping and immunologic relevant proteins were present. However, peptides from TAA could also be detected, proving our method to be a straightforward approach for the identification of in vivo relevant class II ligands of TAA.
Under inflammatory conditions, MHC II expression can be induced in most cell types and tissues by IFNg (17) . We analyzed nine different RCCs by immunohistology and found abundant class II expression on all tumor samples. As class IIpositive tumor cells were found predominantly in outer parts of dissected tumors, one could speculate that leukocytes attracted by the tumor produce IFNg, which acts on neighboring malignant cells. It has been shown that IFNg-producing CD4 + Th1 cells and natural killer cells infiltrate RCC (33) . IFNg may also activate tumor associated macrophages, which in turn may produce proinflammatory cytokines, such as tumor necrosis factor-a and interleukin-1h, supporting tumor angiogenesis (34) . Indeed, we could show that CD68-positive macrophages and CD4-positive T cells were also present in the analyzed sections, and that IFNg mRNA expression was profoundly upregulated in tumor compared with normal samples. This observation was further supported by a general up-regulation of IFN-inducible genes (21) in tumor samples. Thus, our results indicate that IFNg might play an important role in RCC and be the reason for abundant class II expression. It also contradicts the widely held assumption of a prevailing MHC downregulation in tumors.
In the search for peptides from TAA, we identified three ligands accounting for one core sequence from IGFBP3 and one ligand from MMP7. We found these proteins overexpressed in RCC; in addition, they have been described as tumor associated (25 -27) . These peptides bound promiscuously to HLA class II molecules and were able to activate CD4 + T cells from different healthy donors and more rarely from tumor patients. Consequently, we consider our approach a breakthrough in the identification of new class II peptide candidates from TAA for use in clinical vaccination protocols.
